Sun Pharma launches ophthalmic solution in Canada
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The country is sixth among the most affected countries by active cases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Subscribe To Our Newsletter & Stay Updated